Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by analysts at Numis Securities in a research note issued on Wednesday. They presently have a GBX 1,300 ($17.50) target price on the stock. Numis Securities’ target price suggests a potential upside of 13.84% from the company’s current price.
Several other equities analysts also recently commented on HIK. Jefferies Group upped their target price on Hikma Pharmaceuticals from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) and gave the company a “hold” rating in a research report on Monday, December 4th. Morgan Stanley reaffirmed an “equal weight” rating and issued a GBX 1,100 ($14.80) target price on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. Peel Hunt reaffirmed a “hold” rating and issued a GBX 1,390 ($18.71) target price on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 15th. J P Morgan Chase & Co decreased their target price on Hikma Pharmaceuticals from GBX 1,250 ($16.82) to GBX 1,000 ($13.46) and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, decreased their target price on Hikma Pharmaceuticals from GBX 1,060 ($14.27) to GBX 865 ($11.64) and set a “reduce” rating on the stock in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of GBX 1,188.90 ($16.00).
Shares of Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,142 ($15.37) on Wednesday. Hikma Pharmaceuticals has a 52 week low of GBX 906.50 ($12.20) and a 52 week high of GBX 2,346 ($31.57).
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.